摘要
目的:比较阿立哌唑与氯氮平治疗精神分裂症的临床疗效与安全性。方法:将精神分裂症患者100例随机分为阿立哌唑组与氯氮平组。疗程12周。采用阳性与阴性症状量表(PANSS)及治疗中出现的症状量表(TESS)、健康状况问卷(SF-36)评定疗效及不良反应。结果:两组治疗后PANSS评分均显著下降,两组间比较差异无显著性(P>0.05)。不良反应发生率阿立哌唑组显著低于氯氮平组(P<0.05)。结论:阿立哌唑治疗精神分裂症疗效与氯氮平相仿,不良反应少,是一种安全有效的抗精神病药。
Objective： To compare the clinical efficacy and safety between aripiprazole and clozapine in the treatment of schizophrenia. Method： 100 patients with schizophrenia were randomly divided into two groups, aripiprazole group and clozapine group for 12 weeks. Positive and negative symptom scale （PANSS）, treatment emergent symptom scale （TESS）, and short form 36 health survey questionaire （SF-36） were used to evaluate the efficacy or safety. Results：Tile total scores of PANSS obviously decreased in both groups and there was no significant difference between the two groups after treatment （P 〉 0.05）. The incidence rate of side effects in aripiprazole group was significant lower than that in clozapine group （ P 〈 0.05）. Conclusion： Aripiprazole is a safe and effective antipsychotic drug, with similar efficacy as clozapine and fewer side effects in the treatment of schizophrenia.
出处
《临床精神医学杂志》
2008年第1期53-54,共2页
Journal of Clinical Psychiatry
